Michael Gelband’s BioAtla BCAB Stock Holding History

Michael Gelband’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-320	Closed	-$80K	–	1943
2022 Q1	$80K	Buy	+320	New	+$134K	﹤0.01%	2028
2021 Q1	–	Sell	-357	Closed	-$608K	–	2119
2020 Q4	$608K	Buy	+357	New	+$597K	0.01%	1129

Other funds holding BCAB

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Michael Gelband's BCAB Position: Q2 2022 in Review

Michael Gelband sold out of BioAtla (BCAB) in Q2 2022, closing a stake of 320 shares — an estimated $80K sold.

Michael Gelband first reported a position in BCAB in Q4 2020 and held it in 2 quarters. The position peaked at $608K in Q4 2020. 76 funds tracked by Wall St. Rank hold BCAB as of Q2 2022.

Michael Gelband reported no remaining BioAtla position as of Q2 2022 after selling out during the quarter.
Michael Gelband sold 320 BioAtla shares in Q2 2022, an estimated $80K.
Michael Gelband first reported a position in BioAtla in Q4 2020 and held it in 2 quarters.
Michael Gelband's BioAtla position peaked at $608K in Q4 2020.
76 funds tracked by Wall St. Rank held BioAtla as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.